← IPO Calendar
ADARx Pharmaceuticals, Inc.
ADRX
priced
Analyst-verified
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. The company is advancing and expanding its pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx aims to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.
Offering
View source filing- Exchange
- NasdaqAnalyst-verified
- Price
- $17.00Source: Finnhub
- Shares offered
- 26,250,000Source: Finnhub
- Expected date
- 2026-09-25Source: Finnhub
- Priced date
- 2026-09-25Source: Finnhub
- Industry
- BiotechnologyAI-extracted
- Revenue
- —
- Net income
- —
Underwriters
Not yet disclosed.
Filings
- S-1/A 2026-09-14View on EDGAR
- S-1/A 2026-09-14View on EDGAR
- S-1/A 2026-09-21View on EDGAR